Volkswagen and software expert has·to·be cooperate to expand charging infrastructure
Volkswagen is increasing its commitment to charging infrastructures and will work closely with has·to·be GmbH, a leading supplier of operating systems for electric mobility. To this end, the Group is acquiring a minority stake in the company through its subsidiary Elli. Together, has·to·be and Volkswagen will drive forward the expansion of the Europe-wide store network and participate in the rapidly growing market for charging solutions. The Group's own charging stations are also already partly operated with has·to·be software and are thus part of an integrated charging ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190801005351/en/
Handshake Thorsten Nicklass (CEO Elli) and Martin Klässner (CEO has·to·be) Copyright: bernhardhuber.com for Volkswagen AG
“Simple and convenient charging is a must for the rapid breakthrough of e-mobility. Not only do we need more charging stations, but they must also be intelligently networked and function properly. Charging an e-car must become just as natural as charging a smartphone,” says Thomas Ulbrich, Member of the Volkswagen Board of Management responsible for e-mobility. “Together with has·to·be, we want to open up and further develop the fast-growing area of charging infrastructure. We are also using the has·to·be software ourselves. By 2025, we will have built up around 36,000 charging points in Europe across the Group. In the future, charging processes will be even faster and more convenient.”
With over 70 employees from ten countries, has·to·be GmbH manages more than 16,000 charging points, mainly in Europe, but also worldwide - from Norway to Australia and from the United Kingdom to Taiwan. The company’s venture began six years ago with Audi from Ingolstadt as the first customer. Since then, sales have at least doubled every year - mainly due to strong demand from Germany and Switzerland. In the meantime, the spectrum of customers ranges from the automotive industry to energy suppliers and industrial companies. IONITY, Europe's largest fast-charging network, is regarded as the foremost reference: a merger of the BMW Group, Daimler AG, Ford Motor Company and the Volkswagen Group with Audi and Porsche. By the end of 2020, IONITY plans to build a total of 400 fast-charging parks on European motorways. has·to·be software will be used at all stations.
Company founder, Martin Klässner, built prototypes for charging stations in his garage eleven years ago. As a pioneer, Klässner recognized early on the potential of software development for charging infrastructures. Today, has·to·be’s founder is confident: “To shape the future of e-mobility, the partnership with the Volkswagen Group, which is more committed to this technology than any other automotive group, is an essential lever. With Volkswagen on board, we will promote e-mobility in Europe and beyond.”
Networking energy and mobility
Through its subsidiary Elli, the Volkswagen Group is acquiring around a quarter of the shares in has·to·be GmbH. Thorsten Nicklass, CEO of Elli, explains: “Elli has set itself the goal of digitally networking the areas of energy and mobility. We want to make charging simple and inexpensive and establish ourselves as a reliable partner for innovative and sustainable energy solutions for electric vehicles. With our participation in has·to·be, we are now creating the conditions for a seamless customer experience for charging and the integration of further digital services of the Volkswagen Group. This investment is a further logical step in our strategy to intelligently combine charging and energy.”
Volkswagen wants to help e-mobility achieve a worldwide breakthrough, and is pursuing the largest e-mobility offensive in the automotive industry. By 2028, the Group will have launched almost 70 new all-electric models. In the next five years alone, Volkswagen will be investing more than 30 billion euros in this venture. In addition to attractive models, the E-Offensive also includes intelligent charging solutions, energy and digital mobility services.
More about has·to·be GmbH: has-to-be.com
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
bitFlyer Europe and Quazard Partner to Bring First Ever Trading Competition to Botwars Ultimate Trading1.6.2020 07:00:00 EEST | Press release
Leading cryptocurrency exchange bitFlyer, is partnering with crypto-trading game developer Quazard, to bring the first ever gamified trading competition to the Botwars Ultimate Trading universe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200531005005/en/ bitFlyer and Quazard bring the first gamified trading competition to the Botwars Ultimate Trading universe (Graphic: Business Wire) The competition, which launches today, allows Botwars players to compete in a free to enter crypto-trading simulator to win real Bitcoin. This is the first trading competition to launch on Botwars, and the only live trading competition of its type. In Botwars Ultimate Trading, players need to build an army of trading robots (each representing a trade) and lead them into battle to conquer the cryptocurrency markets. Botwars is a real-time, gamified currency trading experience where you will learn new trading skills, unlock powerful new tradin
Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time1.6.2020 04:00:00 EEST | Press release
Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19. The treatment was also able to show improvement in lung lesions to a normal activity level in animal models. The pre-clinical study was conducted in an animal model in collaboration with one of the Korean National Universities, Chungbuk National University College of Medicine. The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment. In comparison to the placebo-controlled group, the research team observed improved recovery in terms of clinical symptom scores such as runny nose, cough and body aches, after the first day of treatment. From the fifth day, significant clinical remission was observed. Reverse transcriptase polymerase chain reaction (RT-PCR) measurement and cell culture-based viral diagnosis were used to a
Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EEST | Press release
Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu
Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom